Regeneron Pharmaceuticals, Inc. (REGN) - שווי שוק לרווח

Regeneron Pharmaceuticals, Inc. - לוגו גרפי של המנפיק REGN

Profit dynamics for Regeneron Pharmaceuticals (REGN) rely on in-house antibody production capabilities with partial utilization of external contractors. High revenue is secured by patent protection for expensive therapies targeting rare pathologies. The strategy is based on the development of oncology and genetic research. The company's P/E fluctuations clearly demonstrate investment payback periods, with 20.10 representing the metric's latest reading.

REGN מכפיל P/E Regeneron Inc. (04.07.2022 - 17.11.2026)

פילוחי מדדים מקיפים ואנליטיקה עבור Regeneron Pharmaceuticals, Inc. (REGN)

ניתוח מקיף של החברה:Regeneron Pharmaceuticals, Inc. - REGN
דוגמת מוצר של Regeneron

The stability of biotechnological drug production in the US and Ireland is directly reflected in the current price-to-earnings valuation of Regeneron Pharmaceuticals (REGN). This indicator determines the investment payback period by comparing the issuer's market capitalization with its quarterly net income. The metric measures the balance between the fundamental stability of the business and the risk of overpaying for the asset. It is critical for investors to find a compromise between the reliability of the drug portfolio and a potential overheating of the share price.